NCT05292950 is a Phase 1, PHASE2 clinical trial of ARO-MUC5AC in Asthma, sponsored by Arrowhead Pharmaceuticals.

Who is sponsoring NCT05292950?

NCT05292950 is sponsored by Arrowhead Pharmaceuticals.

What drugs are being tested in NCT05292950?

Interventions in NCT05292950: ARO-MUC5AC, Placebo.

What condition does NCT05292950 study?

NCT05292950 studies Asthma, Chronic Obstructive Pulmonary Disease.

Is NCT05292950 still recruiting?

NCT05292950 is currently terminated. Last updated 5 November 2025.

Last reviewed 2025-11-05 · How we verify

NCT05292950

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease

Terminated Phase 1, PHASE2 Last updated 5 November 2025

What this trial tests

Phase 1, PHASE2 trial testing ARO-MUC5AC in Asthma in 78 participants. Terminated before completion.

Timeline

27 June 2022

Primary endpoint
12 November 2024

12 November 2024

Quick facts

Lead sponsor	Arrowhead Pharmaceuticals
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	triple
Primary purpose	treatment
Enrollment	78
Start date	27 June 2022
Primary completion	12 November 2024
Estimated completion	12 November 2024
Sites	13 locations across New Zealand, United Kingdom, Poland, South Korea, Thailand, Australia, Spain

Drugs / interventions tested

ARO-MUC5AC — full drug profile →
Placebo

Conditions studied

Asthma — all drugs for Asthma →
Chronic Obstructive Pulmonary Disease — all drugs for Chronic Obstructive Pulmonary Disease →

Sponsor

Arrowhead Pharmaceuticals — full company profile →

Who can join

Adults 18 to 70, any sex, with Asthma or Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of ARO-MUC5AC in normal healthy volunteers (NHVs), patients with moderate-to-severe asthma and patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). In part 1 NHVs will receive a single dose of ARO-MUC5AC or placebo. In part 2 of the study, NHVs, adult patients with asthma, and adult patients with COPD will receive 3 doses of ARO-MUC5AC or placebo.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

The landscape of nanoparticle-based siRNA delivery and therapeutic development.
Moazzam M, Zhang M, Hussain A, Yu X, et al · · 2024 · cited 116× · PMID 38204162 · DOI 10.1016/j.ymthe.2024.01.005
Recent Update on siRNA Therapeutics.
Ebenezer O, Oyebamiji AK, Olanlokun JO, Tuszynski JA, et al · · 2025 · cited 19× · PMID 40331977 · DOI 10.3390/ijms26083456
Development, opportunities, and challenges of siRNA nucleic acid drugs.
Xiao B, Wang S, Pan Y, Zhi W, et al · · 2025 · cited 19× · PMID 39897581 · DOI 10.1016/j.omtn.2024.102437
Delivery of nucleic acids using nanomaterials.
Qin Y, Ou L, Zha L, Zeng Y, et al · · 2023 · cited 14× · PMID 38092998 · DOI 10.1186/s43556-023-00160-0
Changes in mucin expression in the lungs of infant piglets following cardiopulmonary bypass with deep hypothermic circulatory arrest.
Khailova L, Robison J, Ing RJ, Lujan-Osorio SM, et al · · 2026 · PMID 40682213 · DOI 10.1177/10815589251363491

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other Arrowhead Pharmaceuticals trials

Trials by the same sponsor.

NCT07037771 — A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) · Phase 3 · recruiting
NCT05537025 — Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis · Phase 1, PHASE2 · completed
NCT05533294 — Study of ARO-RAGE in Healthy Subjects · Phase 1 · completed
NCT05413135 — Study of ARO-APOC3 in Adults With Dyslipidemia · Phase 2 · completed
NCT05276570 — Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05292950 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arrowhead Pharmaceuticals
Last refreshed: 5 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05292950.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing